EP1853248A1 - Salze, anlagerungs- und komplexverbindungen der guanidinoessigsäure - Google Patents
Salze, anlagerungs- und komplexverbindungen der guanidinoessigsäureInfo
- Publication number
- EP1853248A1 EP1853248A1 EP06707381A EP06707381A EP1853248A1 EP 1853248 A1 EP1853248 A1 EP 1853248A1 EP 06707381 A EP06707381 A EP 06707381A EP 06707381 A EP06707381 A EP 06707381A EP 1853248 A1 EP1853248 A1 EP 1853248A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- salts
- guanidinoacetic
- compounds
- creatine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Definitions
- the present invention is the provision of new salts, addition and complex compounds of guanidinoacetic acid. These have improved physiological and therapeutic properties and are suitable for use as dietary supplements, as feed and in cosmetic or dermatological preparations, with particular emphasis on the pronounced stability and good bioavailability of the salts.
- Guanidinoacetic acid is a naturally occurring substance in humans, which plays a central role in the biosynthesis of creatine. Creatine is of great importance for the energy metabolism of the cell, whereby it can be absorbed by the Nahrang as well as formed by the body itself.
- the biosynthesis starts from glycine and L-arginine.
- the enzyme aminotransferase cleaves the guanidino group of L-arginine and transfers an N-C-N group to the glycine.
- the L-arginine is converted into L-ornithine.
- the guanidinoacetic acid thus formed is converted in the next step, in vertebrates this happens exclusively in the liver, with the help of the enzyme transmethylase in creatine.
- Creatine is a high-energy phosphocreatine in addition to the adenosine triphosphate (ATP) an essential energy reserve of the muscle.
- ATP adenosine triphosphate
- ATP adenosine triphosphate
- the enzyme creatine kinase can transfer a phosphate group to adenosine diphosphate and thus rebuild ATP. This is also called Lohmann reaction.
- creatine monohydrate became a popular nutritional supplement due to its unique function in energy metabolism.
- creatine and its salts have been shown to increase lean muscle mass and muscle performance. It is also known that under the influence of guanidine compounds such as creatine and guanidinoacetic acid, the pancreas secretes more insulin, with guanidinoacetic acid stimulating the release of insulin even better than the creatine itself. Insulin promotes the uptake of glucose and amino acids into the muscle cell and thus promotes protein synthesis. It is also advantageous that the insulin catalyzes the uptake of creatine into the muscle. Furthermore, insulin reduces the rate of degradation of the muscles.
- creatine monohydrate In addition to undoubtedly positive effects, creatine monohydrate also has some disadvantages. The stability of this compound in aqueous solutions is very limited and creatine monohydrate has only a low bioavailability after ingestion. Furthermore, creatine monohydrate is a very expensive substance and the performance improvements achieved in the animal feed sector are almost compensated by the costs.
- guanidinoacetic acid has recently been used as a dietary supplement and feed, which has an astonishing stability compared to creatine in aqueous solution and is much more bioavailable. Guanidinoacetic acid is very efficiently and quickly converted into creatine in the body. Guanidinoacetic acid can therefore be administered with the same effect in much smaller amounts than creatine.
- guanidinoacetic acid is also suitable for cosmetic applications.
- WO 2001/000 203 A1 describes guanidinoacetic acid as an energy-providing system and antioxidant for the upper skin layers, the guanidinoacetic acid being applied mainly in the form of creams, which protects the skin from unfavorable influences such as solar radiation and stress.
- the compound has the disadvantage of very poor solubility in water (1 g in 278 ml of water at 15 ° C.).
- the object of the present invention is to improve the solubility of guanidinoacetic acid in water and to further increase the bioavailability, wherein the known good physiological properties of guanidinoacetic acid should be obtained.
- This object is achieved by the provision of new, stable salts and / or addition and / or complex compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, ⁇ -ketoglutaric acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, Lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid and as sodium, potassium or calcium guanidinoacetate.
- the present invention also relates to a composition having physiological activity containing at least one of the described salts and / or addition and / or complex compounds of guanidinoacetic acid according to the present invention as an effective ingredient.
- the present invention also relates to the use of this composition as a feed, as a dietary supplement or in the medical field and in particular in the form of powders, granules, lozenges, capsules, pellets, solutions, Juices or jelly products.
- this composition may well be advisable to use the salts and / or addition compounds and / or complex compounds of guanidinoacetic acid in combination with other physiologically active ingredients, in particular carbohydrates, fats, amino acids, proteins, vitamins, minerals, Trace elements and their derivatives and any mixtures thereof are particularly suitable.
- the present invention thus also provides animal feed, nutritional supplements and medicaments containing the salts, addition or complex compounds according to the invention.
- the salts and / or addition and / or complex compounds of guanidinoacetic acid can be used in a relatively wide dosing range, with both the single doses and the daily doses are not subject to serious restrictions. According to the claimed use in single doses of 0.001 to 1 g / kg body weight and / or in daily doses of 0.001 to 50 g instead.
- the use according to the invention takes place as a dietary supplement in humans, which is preferably taken into consideration, the use in particular in school, sports, convalescence and / or geriatrics is an option.
- the use of the salts and / or addition and / or complex compounds of guanidinoacetic acid as feed additive is to be regarded as preferred especially for animals in competitive sports.
- the novel salts and / or addition and / or complex compounds of guanidinoacetic acid can be used as feed additive for wet and dry food for dogs and cats, wherein v. a. positive effects on the immune system and the general condition of the animals are to be noted.
- the claimed salts and / or addition and / or complex compounds of guanidinoacetic acid are also suitable as feed additives for breeding and fattening animals and, in this context, pigs, horses, poultry and fish in particular, the use of which as a substitute for animal and / or fishmeal and products derived therefrom has proven to be particularly advantageous.
- the replacement can take place as a partial or full replacement.
- the salts and / or addition and / or complex compounds of guanidinoacetic acid can also be used in cosmetic or dermatological preparations in the context of the present invention.
- This results in the high stability and solubility of the claimed compounds clearly advantages for the formulation, with respect to the efficacy and synergistic effects between guanidinoacetic acid and the respective reactants are observed.
- the present invention with the new, stable salts and / or addition and / or complex compounds of guanidinoacetic much more than just new alternatives to the known creatine compounds and the free guanidinoacetic, since the properties of the new salts and / or addition and / or complex compounds v. a. overcome the disadvantages of the known compounds in the preferred application areas and thereby represent very significant improvements.
- compositions of savory formulations whose ingredients are simply dry blended at room temperature. It is recommended that the powdered formulations be dissolved in 200 ml of fruit juice and / or water before being taken orally.
- guanidinoacetic acid citrate is introduced homogeneously into a commercially available water-in-oil base cream.
- the cream is u. a. for the treatment of sensitive, deficient and hypoactive skin conditions. Furthermore, against premature skin aging and environmental negative skin changes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL06707381T PL1853248T3 (pl) | 2005-03-04 | 2006-03-02 | Zastosowanie soli, addycyjnych i kompleksowych związków kwasu guanidynooctowego |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005009990A DE102005009990A1 (de) | 2005-03-04 | 2005-03-04 | Salze, Anlagerungs- und Komplexverbindungen der Guanidinoessigsäure |
PCT/EP2006/001908 WO2006092298A1 (de) | 2005-03-04 | 2006-03-02 | Salze, anlagerungs- und komplexverbindungen der guanidinoessigsäure |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1853248A1 true EP1853248A1 (de) | 2007-11-14 |
EP1853248B1 EP1853248B1 (de) | 2008-10-29 |
Family
ID=36129675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06707381A Active EP1853248B1 (de) | 2005-03-04 | 2006-03-02 | Verwendung der SALZE, ANLAGERUNGS- UND KOMPLEXVERBINDUNGEN DER GUANIDINOESSIGSÄURE |
Country Status (18)
Country | Link |
---|---|
US (1) | US8153685B2 (de) |
EP (1) | EP1853248B1 (de) |
JP (1) | JP4928473B2 (de) |
CN (1) | CN101132786B (de) |
AT (1) | ATE412410T1 (de) |
AU (1) | AU2006220005B2 (de) |
BR (1) | BRPI0609372B1 (de) |
CA (1) | CA2600890C (de) |
DE (2) | DE102005009990A1 (de) |
DK (1) | DK1853248T3 (de) |
ES (1) | ES2313616T3 (de) |
HK (1) | HK1104782A1 (de) |
PL (1) | PL1853248T3 (de) |
PT (1) | PT1853248E (de) |
RU (1) | RU2402921C2 (de) |
UA (1) | UA97090C2 (de) |
WO (1) | WO2006092298A1 (de) |
ZA (1) | ZA200706998B (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2422049C2 (ru) * | 2005-08-02 | 2011-06-27 | Альцхем Тростберг Гмбх | Жидкая композиция, основанная на компоненте гуанидинуксусной кислоты |
DE102006009373A1 (de) * | 2006-03-01 | 2007-09-06 | Degussa Gmbh | Fertigfutter für Haustiere |
DE102007004781A1 (de) * | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels |
DE102007034102A1 (de) * | 2007-07-21 | 2009-01-22 | Alzchem Trostberg Gmbh | Abriebfeste und rieselfähige Glycocyamin-haltige Formlinge und Verfahren zu deren Herstellung |
DE102007062288A1 (de) | 2007-12-21 | 2009-06-25 | Alzchem Trostberg Gmbh | Kreatin-Zubereitung und Verfahren zu deren Herstellung |
US7874536B2 (en) * | 2008-09-26 | 2011-01-25 | Groover David O | Angle ceiling hanger or bracket |
EP2519115B1 (de) | 2009-12-29 | 2017-02-15 | Hill's Pet Nutrition, Inc. | Zusammensetzungen mit pyruvat für haustiere und anwendungsverfahren dafür |
CN101912044A (zh) * | 2010-08-13 | 2010-12-15 | 青岛天通生物科技有限公司 | 促肌肉生成的组合物及其制备方法 |
CN104605161B (zh) * | 2015-01-23 | 2018-02-27 | 长沙兴嘉生物工程股份有限公司 | 胍基乙酸配合物的制备方法及其应用 |
DE102019118898A1 (de) | 2019-07-12 | 2021-01-14 | Alzchem Trostberg Gmbh | Konzentrat zur Herstellung einer Tränklösung |
DE102019120246A1 (de) | 2019-07-26 | 2021-01-28 | Alzchem Trostberg Gmbh | Verfahren zur Fütterung von Geflügel |
DE102019120244A1 (de) * | 2019-07-26 | 2021-01-28 | Alzchem Trostberg Gmbh | Verwendung einer Zusammensetzung zur Verminderung des Federverlustes von Vögeln |
DE102019120249A1 (de) * | 2019-07-26 | 2021-01-28 | Alzchem Trostberg Gmbh | Verwendung einer Zusammensetzung zur Reduzierung der Feuchtigkeit und des Stickstoffgehalts in Faeces von Geflügel |
DE102019121526A1 (de) | 2019-08-09 | 2021-02-11 | Alzchem Trostberg Gmbh | Konzentrat zur Herstellung von Tränklösungen (II) |
DE102021126581A1 (de) | 2021-10-13 | 2023-04-13 | Alzchem Trostberg Gmbh | Verwendung eines Futtermitteladditives in energiearmen Futter für Schweine |
CN114751845B (zh) * | 2022-06-13 | 2022-09-20 | 北京君德同创生物技术股份有限公司 | 一种易溶的胍基乙酸络合物的合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1195199A (en) * | 1966-11-25 | 1970-06-17 | Horlicks Pharmaceuticals Ltd | Improvements in Compositions comprising Insulin. |
GB1195200A (en) * | 1967-02-07 | 1970-06-17 | Horlicks Pharmaceuticals Ltd | Pharmaceutical Compositions. |
JPS61231996A (ja) * | 1985-04-04 | 1986-10-16 | Kikkoman Corp | グアニジノ酢酸分解酵素の安定化法 |
IT1237519B (it) * | 1989-11-27 | 1993-06-08 | Impiego dell'acido guanidinacetico per indurre un incremento del contenuto muscolare di creatina | |
JPH09202710A (ja) * | 1995-11-20 | 1997-08-05 | Kao Corp | しわ改善剤 |
US5939078A (en) * | 1995-11-20 | 1999-08-17 | Kao Corporation | Wrinkle-care product |
JP3708229B2 (ja) * | 1996-07-04 | 2005-10-19 | 花王株式会社 | 毛髪処理剤組成物 |
US6242491B1 (en) * | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
US6855727B2 (en) * | 2000-12-04 | 2005-02-15 | Yaizu Suisankagaku Industry Co., Ltd. | Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect |
ATE457726T1 (de) | 2002-06-19 | 2010-03-15 | Nutricia Nv | Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen |
DK1758463T3 (da) * | 2004-06-09 | 2008-05-05 | Alzchem Trostberg Gmbh | Guanidinoeddikesyre som fodermiddeltilsætning |
-
2005
- 2005-03-04 DE DE102005009990A patent/DE102005009990A1/de not_active Withdrawn
-
2006
- 2006-03-02 WO PCT/EP2006/001908 patent/WO2006092298A1/de active Application Filing
- 2006-03-02 UA UAA200710713A patent/UA97090C2/ru unknown
- 2006-03-02 EP EP06707381A patent/EP1853248B1/de active Active
- 2006-03-02 AT AT06707381T patent/ATE412410T1/de active
- 2006-03-02 CN CN2006800071547A patent/CN101132786B/zh active Active
- 2006-03-02 DE DE502006001941T patent/DE502006001941D1/de active Active
- 2006-03-02 RU RU2007136761/13A patent/RU2402921C2/ru active
- 2006-03-02 PT PT06707381T patent/PT1853248E/pt unknown
- 2006-03-02 AU AU2006220005A patent/AU2006220005B2/en active Active
- 2006-03-02 BR BRPI0609372-8A patent/BRPI0609372B1/pt active IP Right Grant
- 2006-03-02 JP JP2007557425A patent/JP4928473B2/ja active Active
- 2006-03-02 US US11/885,375 patent/US8153685B2/en active Active
- 2006-03-02 CA CA2600890A patent/CA2600890C/en active Active
- 2006-03-02 PL PL06707381T patent/PL1853248T3/pl unknown
- 2006-03-02 DK DK06707381T patent/DK1853248T3/da active
- 2006-03-02 ES ES06707381T patent/ES2313616T3/es active Active
-
2007
- 2007-08-21 ZA ZA200706998A patent/ZA200706998B/xx unknown
- 2007-11-29 HK HK07113011A patent/HK1104782A1/xx not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2006092298A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2006220005A1 (en) | 2006-09-08 |
HK1104782A1 (en) | 2008-01-25 |
DE502006001941D1 (de) | 2008-12-11 |
JP2008531029A (ja) | 2008-08-14 |
DK1853248T3 (da) | 2009-02-16 |
CN101132786A (zh) | 2008-02-27 |
ES2313616T3 (es) | 2009-03-01 |
PL1853248T3 (pl) | 2009-01-30 |
JP4928473B2 (ja) | 2012-05-09 |
BRPI0609372B1 (pt) | 2020-09-08 |
CA2600890A1 (en) | 2006-09-08 |
EP1853248B1 (de) | 2008-10-29 |
US8153685B2 (en) | 2012-04-10 |
ATE412410T1 (de) | 2008-11-15 |
UA97090C2 (ru) | 2012-01-10 |
WO2006092298A1 (de) | 2006-09-08 |
ZA200706998B (en) | 2008-11-26 |
US20080161387A1 (en) | 2008-07-03 |
CN101132786B (zh) | 2011-04-13 |
PT1853248E (pt) | 2009-02-09 |
CA2600890C (en) | 2014-07-15 |
RU2007136761A (ru) | 2009-04-10 |
DE102005009990A1 (de) | 2006-09-07 |
AU2006220005B2 (en) | 2011-07-21 |
RU2402921C2 (ru) | 2010-11-10 |
BRPI0609372A2 (pt) | 2010-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1853248B1 (de) | Verwendung der SALZE, ANLAGERUNGS- UND KOMPLEXVERBINDUNGEN DER GUANIDINOESSIGSÄURE | |
EP1758463B1 (de) | Guanidinoessigsäure als futtermittelzusatz | |
EP1909601B1 (de) | Flüssig-formulierung auf basis einer guanidinoessigsäure-komponente | |
EP1991065B1 (de) | Fertigfutter für haustiere | |
EP2114174B1 (de) | Verwendung von guanidinoessigsäure(-salzen) in kombination mit betain und/oder cholin zur herstellung eines gesundheitsfördernden mittels | |
WO2005082165A1 (de) | Verwendung von guanidin-verbindungen als physiologisches stärkungsmittel in form von nahrungsergänzungsmitteln, futtermittelzusätzen, in kosmetischen zubereitungen und als pflanzenstärkungsmittel | |
DE102007030495A1 (de) | Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände | |
EP2234506B1 (de) | Zubereitung umfassend eine kreatin-komponente, verfahren zu deren herstellung und ihre verwendung | |
EP2094116B1 (de) | Feste oder wässrige alkalische zubereitung umfassend eine kreatin-komponente, verfahren zu deren herstellung und ihre verwendung | |
DE102007053369A1 (de) | Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit | |
DE19836450A1 (de) | Stabile, Brenztraubensäure (Salze) enthaltende Formulierung für die Tierernährung | |
DE102006035801A1 (de) | Flüssig-Formulierung auf Basis einer Guanidinoessigsäure-Komponente | |
WO1999027799A1 (de) | Verfahren zur herstellung und verwendung von lysinformiat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070810 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1104782 Country of ref document: HK |
|
RTI1 | Title (correction) |
Free format text: USE OF THE SALTS, ADDITION COMPOUNDS AND COMPLEX COMPOUNDS OF GUANIDINOACETIC ACID |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REF | Corresponds to: |
Ref document number: 502006001941 Country of ref document: DE Date of ref document: 20081211 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20080403579 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1104782 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20090128 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2313616 Country of ref document: ES Kind code of ref document: T3 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20081029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20090730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20140326 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150302 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230323 Year of fee payment: 18 Ref country code: FR Payment date: 20230322 Year of fee payment: 18 Ref country code: DK Payment date: 20230323 Year of fee payment: 18 Ref country code: CZ Payment date: 20230220 Year of fee payment: 18 Ref country code: AT Payment date: 20230322 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230220 Year of fee payment: 18 Ref country code: SE Payment date: 20230314 Year of fee payment: 18 Ref country code: PT Payment date: 20230216 Year of fee payment: 18 Ref country code: PL Payment date: 20230217 Year of fee payment: 18 Ref country code: GR Payment date: 20230327 Year of fee payment: 18 Ref country code: GB Payment date: 20230321 Year of fee payment: 18 Ref country code: DE Payment date: 20230321 Year of fee payment: 18 Ref country code: BE Payment date: 20230321 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230321 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230328 Year of fee payment: 18 Ref country code: ES Payment date: 20230527 Year of fee payment: 18 Ref country code: CH Payment date: 20230402 Year of fee payment: 18 |